Ingenus Pharmaceuticals LLC and Leiutis Pharmaceuticals LLP filed a federal lawsuit in Illinois alleging that Nexus Pharmaceuticals Inc.’s proposed generic version of cyclophosphamide infringes a patent for the intravenous treatment of malignant cancers.
Nexus wants to sell copies of the drug’s 500-milligrams-per-2.5-milliliters and 1-mg/5-mL doses, according to a complaint filed Wednesday in the US District Court for the Northern District of Illinois. The suing companies are asking the court to bar Nexus from doing so.
The injectable solution is used to treat malignant lymphomas, multiple myeloma, leukemias, neuroblastoma,, eye cancer that starts in the retina, and other cancers, the ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.